This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Koh, K. K. Search for Related Content PubMed PubMed Citation Articles by Koh, K. K.

(Circulation Research. 2006;98:e49.)
© 2006 American Heart Association, Inc.

Letter to the Editor

Fenofibrate, Statins, and Inflammation

Kwang Kon Koh

Professor of Medicine, Director, Vascular Medicine and Atherosclerosis Unit, Cardiology, Gil Heart Center, Gachon Medical School, Incheon, Korea

An extract of the first 100% of the full text is provided, because this article has no abstract.

To the Editor:

I recently read the review by Berg et al, about tissue, inflammation, and cardiovascular disease.¹ Although the review discusses our research on ligands for peroxisome proliferator activated receptor (PPAR), we used fenofibrate, a PPAR- activator, not glitazones, PPAR- agonists, as the review suggests.² We also found that statins non-significantly lower serum adiponectin levels, not as the review states that statins marginally increase adiponectin levels.³

1. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005; 96: 939–949.[Abstract/Free Full Text]

2. Koh KK, Ahn JY, Han SH, Jin DK, Kim HS, Lee KC, Shin EK, Sakuma I. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis. 2004; 174: 379–383.[Medline] [Order article via Infotrieve]

3. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004; 110: 3687–3692.[Abstract/Free Full Text]